Clostridium difficile (C. difficile) is considered to be the major cause of the antibiotic-associated diarrhea and pseudomembranous colitis in animals and humans. The prevalence of C. difficile infections (CDI) has been increasing since 2000. Two exotoxins of C. difficile, Toxin A (TcdA) and Toxin B (TcdB), are the main virulence factors of CDI, which can induce glucosylation of Rho GTPases in host cytosol, leading to cell morphological changes, cell apoptosis, and cell death. The mechanism of TcdB-induced cell death has been investigated for decades, but it is still not completely understood. It has been reported that TcdB induces endoplasmic reticulum stress via PERK-eIF2α signaling pathway in CT26 cell line (BALB/C mouse colon tumor cells). In this study, we found that salubrinal, a selective inhibitor of eIF2α dephosphorylation, efficiently protects CT26 cell line against TcdB-induced cell death and tried to explore the mechanism underlying in this protective effect. Our results demonstrated that salubrinal protects CT26 cells from TcdB-mediated cytotoxic and cytopathic effect, inhibits apoptosis and death of the toxin-exposed cells via caspase-9-dependent pathway, eIF2α signaling pathway, and autophagy. These findings will be helpful for the development of CDI therapies.
Introduction
Clostridium difficile (C. difficile), a Gram-positive, spore-forming pathogenic bacillus, is the major cause of antibiotic-associated diarrhea and pseudomembranous colitis in humans and animals [1] [2] [3] . Clostridium difficile infections (CDI) have been increasing in prevalence since 2000 and becoming less responsive to treatments [4] [5] [6] . Two cytotoxins, Toxin A (TcdA) and Toxin B (TcdB), are the major virulence factors of CDI [7, 8] . Both TcdA and TcdB belong to the family of clostridial glucosylating toxins, which are able to modify Rho GTPases in host cytosol by mono-O-glucosylation [9] [10] [11] , resulting in inhibition of the signaling and regulatory function of these target proteins [9, 12] .
The C. difficile toxins are multi-domain proteins containing four functional domains: glucosyltransferase domain (GTD), cysteine protease domain (CPD), translocation domain (TD), and receptor binding domain (RBD) [13, 14] . The molecular mode of action of TcdA and TcdB is not completely understood, but it is widely accepted that the toxins first bind to cell surface receptors by RBD and then enter the host cells via endocytosis [15] , after translocation from endosomal compartments, GTD is released into host cytosol [16] through autocleavage by CPD [17] [18] [19] [20] . Once released into cytosol, the GTD targets the Rho GTPases and induces glucosylation at Thr 35 /Thr 37 of the GTPases [10] , leading to the block of all the Rho-dependent signaling pathways and eventually leading to cell apoptosis and cell death [21] .
Salubrinal, with a chemical name of 3-phenyl-N-[2,2,2-trichloro-1-[[(8-quinolinylamino) thioxomethyl] amino] ethyl] 2-propenamide ( Fig. 1) , is a drug which acts as an inhibitor of serine/threonine-protein phosphatase PP1 and selectively inhibits the dephosphorylation of phosphorylated α subunit of eukaryotic initiation factor 2 (phospeIF2α) [22] . Enhancement of eIF2α phosphorylation results in a halt in protein synthesis, permitting cells to recover from consequences of endoplasmic reticulum (ER) stress that can otherwise lead to apoptosis [23] . Until now, the reported roles of salubrinal include acceleration of bone wounds healing in mice [24] , stimulation of osteoblast differentiation [25, 26] , attenuation of nuclear factor κB-mediated molecular signals [27] , protection against cell apoptosis [28, 29] , and so on. Recently, upregulation of phosp-eIF2α was found in TcdB-exposed CT26 cell line (BALB/C mouse colon tumor cells) [30] and in mice cecum and colon tissues receiving C. difficile VPI10463 vegetative cells [31] , which seemed to protect host cells and animals. These raise the prospect that salubrinal might have protective effect against TcdB-induced cell death. This study focuses on the potential protective role of salubrinal against TcdB-induced CT26 cell death and tries to reveal its underlying mechanism, which would contribute to the development of CDI therapies.
Materials and Methods
Mammalian cell line and bacteria CT26 cell line (BALB/C mouse colon tumor cells) was purchased from the Cell Resource Center of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's minimum Eagle's medium supplemented with 10% fetal bovine serum at 37°C with 5% CO 2 . Bacillus megaterium strain WH320 (MoBiTec, Gottingen, Germany) was cultured in Luria-Bertani (LB) medium at 37°C.
Antibodies
Primary antibodies are shown as follows: rabbit anti-TcdB GTD polyclonal antibody (ab83066, Abcam, Cambridge, UK); anti-TcdB GTD VHH monoclonal antibody (kindly provided by Dr Hanping Feng, University of Maryland Dental School, Baltimore, USA); rabbit antieIF2α monoclonal antibody (Cell Signaling, Beverly, USA); rabbit anti-phosp-eIF2α monoclonal antibody (Cell Signaling); rabbit anticleaved caspase-9 polyclonal antibody (Cell Signaling); rabbit anti-LC3B monoclonal antibody (Cell Signaling); rabbit anti-β-actin monoclonal antibody (Cell Signaling); mouse anti-Rac1 monoclonal antibody (BD Biosciences, Franklin Lakes, USA); anti-CHOP mouse monoclonal antibody (Cell Signaling); and rabbit anti-Bcl2 polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, USA).
The secondary antibodies are horseradish peroxidase (HRP)-conjugated goat anti-Llama IgG H&L antibody; HRP-conjugated goat anti-rabbit IgG H&L antibody; and HRP-conjugated goat antimouse IgG H&L antibody, which were all purchased from Abcam.
Recombinant TcdB expression and purification
The plasmid encoding full-length recombinant TcdB was kindly provided by Dr Hanping Feng. The plasmid was transformed into B. megaterium protoplast according to the manufacturer's instruction (MoBiTec). The transformed B. megaterium colonies were transferred to the LB broth containing 10 µg/ml tetracycline and incubated at 37°C with constant shaking at 250 rpm. TcdB protein was induced by addition of xylose (5 mg/ml). The recombinant TcdB was expressed with C-terminal His 6 tags. The purification of His-tag proteins was performed using Ni 2+ affinity chromatography.
After purification, the protein was dialyzed against phosphate buffered saline (PBS) buffer and finally stored at −80°C.
Cytotoxic and cytopathic assays
The cytotoxic effect induced by salubrinal or TcdB was analyzed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] viability assay as described previously [32] . Briefly, 1 × 10 4 CT26
cells were seeded in a 96-well plate and cultured at 37°C with 5% CO 2 for 24 h. Serial dilutions of salubrinal (Sigma-Aldrich, St Louis, USA) or/and TcdB were added to the cells and incubated at 37°C for indicated time. MTT (20 µl; 5 mg/ml) was then added and the plate was further incubated at 37°C for another 4 h. The formazan was solubilized with dimethyl sulphoxide and absorbance at 490 nm was measured using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, USA). Cell viability was expressed as the percentage of the survival cells compared with untreated cells. The cytopathic effect induced by salubrinal and TcdB was measured by cell rounding assay. Briefly, CT26 cells were treated with different doses of salubrinal with or without TcdB, or different doses of TcdB with or without salubrinal for indicated time. Cell rounding was visualized by phase-contrast microscopy (Olympus, Tokyo, Japan). The experiments were repeated three times, and triplicate wells were assessed for the MTT assay and cell rounding assay in each experiment.
In vitro autocleavage assay
The in vitro autocleavage assay was performed as described previously [17, 33] . Briefly, 10 µg of recombinant TcdB was diluted in 20 mM Tris buffer (pH 7.4) to a final volume of 100 µl with or without 20 µM salubrinal. Cleavage was initiated by addition of 10 µM inositol hexakisphosphate (InsP 6 ) (Sigma-Aldrich). The mixture was incubated at room temperature overnight. The reaction was stopped by addition of 5 × sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer, and the autocleavage was analyzed by western blot analysis using anti-TcdB GTD (the GTD of TcdB, amino acids 1-543) monoclonal antibody (Abcam).
In vitro glucosylation assay
The in vitro glucosylation assay was performed with CT26 cell lysates. Briefly, 2 × 10 5 CT26 cells were seeded in a 100 mm plate and cultured at 37°C with 5% CO 2 for 48 h before being harvested by a plastic scraper. The cell pellets were then resuspended in a reaction buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5, 100 mM KCl, 1 mM MnCl 2, and 2 mM MgCl 2 ) and lysed by passing through a 30-G needle 40 times. After centrifugation, the supernatant was used as the cytosolic fraction. For the glucosylation assay, the cytosolic fraction was incubated with 100 μg/ml TcdB at room temperature overnight. The reaction was terminated by addition of 5 × SDS-PAGE loading buffer and boiled for 5 min. Finally, the samples were analyzed by western blot analysis using anti-unglucosylated Rac1 mAb (BD Biosciences). Cell surface binding analysis Measurement of GTD release into the host cytosol
were seeded in a 100 mm dish and incubated at 37°C with 5% CO 2 for 48 h. Then the cells were exposed to 2 µg/ml of TcdB in the presence or absence of 20 µM salubrinal and incubated for 2 h at 37°C. After toxin treatment, the cells were washed with PBS three times and harvested using a plastic scraper. The cytosolic fraction of the toxin-exposed cells was separated using Membrane and cytoplasm protein extraction kit (KeyGen BioTech, Nanjing, China). The GTD in the cytosolic fraction was precipitated using a goat anti-rabbit IgG coated Dynabeads M-280 (Life Technologies, Carlsbad, USA) according to the manufacturer's instructions. Briefly, the beads were washed with washing buffer (20 mM PBS, 0.1% BSA, and 2 mM ethylenediaminetetraacetic acid, pH 7.4) before incubation with primary antibodies (rabbit antiTcdBGTD polyclonal antibody) at 4°C overnight. For immunoprecipitation, the primary antibody coated beads were incubated with the cytosolic fraction of the toxin-exposed cells at 4°C overnight. Then, the beads were collected with a magnet (Life Technologies) and washed. The samples were subsequently analyzed by western blot analysis using the anti-TcdB GTD VHH antibody.
Assessment of cell apoptosis
Apoptosis was measured by Annexin V apoptosis assay using Annexin V-FITC assay kit (Invitrogen, Carlsbad, USA) and events in the hypodiploid region of cellular deoxyribonucleic acid (DNA) profiles. Annexin V-FITC apoptosis detection and sub-G1 events determination were performed as previously described [30, 34] . The results were analyzed by a flow cytometer (Beckman, Brea, USA) and Win-MDI software (Scripps Research Institute, Jupiter, USA). The results were shown as percentages of total events.
LDH release assay
The release of lactate dehydrogenase (LDH) was measured using the LDH assay kit (Beyotime, Haimen, China) following the manufacturer's instructions. Briefly, 1 × 10 4 CT26 cells were seeded in a 96-well plate and incubated at 37°C with 5% CO 2 for 48 h. Then the cells were exposed to TcdB at serial concentrations with or without 20 µM salubrinal for 24 h. After the toxin treatment, 30 µl/well of the medium were mixed with 60 µl reaction buffer in a new 96-well plate and incubated at room temperature for 30 min. The absorbance at 490 nm was measured using a SpectraMax M5 microplate reader (Molecular Devices).
Statistical analysis
Results are shown as the mean ± SD unless otherwise indicated. Statistical analyses were performed using One-way ANOVA followed by Tukey or Dunnett post-hoc test. P < 0.05 was considered to be statistically significant.
Results

Recombinant TcdB expression and purification
Recombinant full-length TcdB was expressed in a B. megaterium expression system as previously described [35] and purified using Ni 2+ affinity chromatography. Purification of TcdB resulted in a single band on Coomassie blue stained SDS-PAGE gels with molecular size of~270 kDa ( Fig. 2A) .
Salubrinal protects CT26 cells from TcdB-induced cytotoxic and cytopathic effects
The damage of salubrinal toward CT26 cells was dose-dependent as evidenced by morphological changes and survival inhibition ( To investigate whether salubrinal can protect CT26 against TcdB-induced cytotoxic and cytopathic effect, CT26 cells were exposed to TcdB in the presence of 20 µM salubrinal, and then the morphology, viability and LDH release of the intoxicated cells were analyzed. As shown in Fig. 2D , TcdB caused 100% cell rounding at a concentration of 1 ng/ml in 5 h, while in the presence of 20 µM salubrinal, 100-fold higher concentration of TcdB (100 ng/ml) was needed to induce 100% cell rounding. Furthermore, the MTT assay showed that, in the presence of 20 µM salubrinal, the viability of CT26 cells was significantly increased when treated with different concentrations of TcdB (0.1, 1, 10, 100, and 1000 ng/ml) for 24 h (Fig. 2E) . These results demonstrated that salubrinal can protect CT26 cells against TcdB-induced cytotoxic and cytopathic effects.
Effect of salubrinal on TcdB-induced CT26 cell death
Cell damage following TcdB treatment was assessed by measurement of LDH released into the medium solution, which is an index of cytotoxicity. As shown in Fig. 2F , TcdB exposure caused a significant LDH release in a TcdB concentration-dependent manner, which was obviously blocked by 20 µM salubrinal, demonstrating the protective effect of salubrinal against TcdB-induced cell death.
Furthermore, the TcdB-induced apoptotic cell death was determined by the sub-G 1 DNA content and surface exposure phosphatidylserin assays. First, CT26 cells were double-labeled with Annexin V and PI, and then analyzed by flow cytometry. After 12, 24, and 36 h exposure to TcdB, the ratio of Annexin V-positive CT26 cells was 39.43% ± 0.83%, 44.32% ± 1.22%, and 68.96% ± 2.71%, respectively, however the addition of salubrinal significantly decreased the ratio to 26.5% ± 3.99%, 26.01% ± 1.68%, and 32.6% ± 0.40%, respectively (Fig. 3A,B) . Figure. 3C,D showed cell cycle profiles of TcdB treated cells with or without salubrinal. In contrast to the cells treated with TcdB alone, the administration of salubrinal significantly reduced the percentage of sub-G 1 population in 24 and 36 h TcdB-intoxicated cells, which was consistent with the Annexin V assay. These results demonstrate that salubrinal is able to protect CT26 cells from TcdB-induced cell death.
Salubrinal does not inhibit the activity of TcdB
To determine whether salubrinal would influence the structure and function of TcdB, the cell-binding activity, glucosyltransferase activity, cysteine protease activity, and GTD release were examined. In cell-binding analysis, CT26 cells were incubated with Alexa ® Fluor A488-labeled TcdB RBD and imaged by fluorescence microscopy. As shown in Fig. 4A , TcdB RBD , in the presence of 20 µM salubrinal, was able to bind to the surface of CT26 cells in the same pattern as that without salubrinal. Therefore, it is assumed that salubrinal does not inhibit the cell binding of TcdB.
The glucosyltransferase activity of TcdB was determined using in vitro glucosylation assay. TcdB efficiently induced Rac1 glucosylation either in the presence or in the absence of salubrinal (Fig. 3B) . Finally, the autoprocessing of TcdB by CPD (Fig. 4C) and release of GTD into host cytosol (Fig. 3D) were tested by in vitro autocleavage assay. As shown in Fig. 4C ,D, salubrinal did not inhibit the InsP 6 -induced TcdB autocleavage and release of the 63 kDa fragment of GTD into the host cytosol. Based on the results above, it is concluded that salubrinal does not influence the structure and function of TcdB.
Mechanism of the protective effect of salubrinal
Clostridium difficile TcdB targets Rho-GTPase proteins in the host cytosol, resulting in morphological change, secretion inhibition, apoptosis, phagocytosis disregulation, and death of the host cells. Therefore, whether salubrinal could prevent the glucosylation of Rho proteins caused by TcdB was checked. As shown in Fig. 5A , obvious glucosylation of Rac1 could be observed after cells were exposed to TcdB alone for 12, 24, and 36 h. However, the level of Rac1 glucosylation induced by TcdB was remarkably reduced in the presence of 20 µM salubrinal at all of the three incubation time points, even though the level of Rac1 glucosylation was still much higher than that of the untreated cell (cell only) or treated with salubrinal only (salubrinal only). Since caspase-9 was reported to be activated in TcdB-exposed endothelial cells and mediate TcdB-induced apoptosis [36, 37] , the cleavage of pro-caspase-9 in cells treated with TcdB in the presence . LDH release of TcdB-intoxicated CT26 cells in the presence or absence of salubrinal. After exposure to indicated concentrations of TcdB with or without salubrinal for 24 h, the cell supernatants were harvested and the levels of LDH were measured. Data are shown as the mean ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. LDH, lactate dehydrogenase .
of salubrinal was assessed by western blot analysis. The results indicated that, compared with TcdB treatment only, salubrinal could obviously blunt the TcdB-induced cleavage of caspase-9 at 12 and 24 h (Fig. 5A,C) . After 36 h of treatment, the level of cleaved caspase-9 in CT26 cells exposed to TcdB alone was almost the same as that in cells exposed to TcdB together with 20 µM salubrinal. These results demonstrated that the protective effect of salubrinal against TcdB-mediated cell apoptosis is associated with caspase-9-dependent apoptotic cell death pathway. Our group has previously revealed that TcdB can induce ER stress in CT26 cell line via PERK-eIF2α signaling pathway [30] . Based on the assumption that salubrinal could selectively elevate the phosphorylation level of eIF2α and permit cells recover from apoptosis caused by ER stress, whether 20 µM of salubrinal could affect the phosphorylation level of eIF2α in TcdB-intoxicated CT26 cells was assessed. As shown in Fig. 5B ,D, after 12 h of exposure to TcdB, the ratio of phosp-eIF2α/eIF2α was markedly increased both in the presence and in the absence of salubrinal when compared with the untreated cells (cell only). Interestingly, the ratio of phospeIF2α/eIF2α was dramatically decreased with a longer TcdB treatment time (24 h ), but the elevation of phophorylation of eIF2α by salubrinal was not apparent when the treatment time was extended to 36 h (Fig. 5B,D) , suggesting that salubrinal is able to regulate p-eIF2α processing and protects cells from ER stress-induced cell death during the 12 and 24 h of TcdB treatment.
C/EBP-homologous protein (CHOP) is considered to be a key mediator of ER stress-induced apoptosis. CHOP-mediated apoptosis is related with downregulation of Bcl-2 [38] [39] [40] . Therefore, the protein expression levels of CHOP and Bcl-2 in TcdB and/or salubrinaltreated CT26 cells were measured using western blot analysis (Fig. 5B) . Unexpectedly, the protein expression levels of CHOP in the CT26 cells exposed to TcdB only were significantly decreased at every time point, which was consistent with our previous work [30] . Furthermore, the addition of salubrinal did not alter the decrease of CHOP induced by TcdB. After exposure to TcdB only for a certain time, the expression of Bcl-2 decreased in a toxin treated timedependent manner, and comparatively, the expression level of Bcl-2 increased when treated with TcdB and salubrinal for 12 and 24 h (Fig. 5B) .
Salubrinal abrogates autophagy in TcdB-intoxicated cells
Autophagy has not been reported in TcdB-intoxicated cells so far. Moreover, recent studies have shown that salubrinal can abrogate autophagy caused by various factors [41] [42] [43] , thus we assumed that Then, the cells were stained with propidium iodide, and DNA fluorescence was analyzed by flow cytometry. Events within the M1 region reflect DNA fragmentation due to apoptotic cell death. *P < 0.05; ***P < 0.001. DNA, deoxyribonucleic acid.
salubrinal might be able to protect autophagy of TcdB-intoxicated cells. To explore whether TcdB induces autophagy and whether salubrinal abrogates autophagy of TcdB-exposed cells, the expression levels of LC3B-I and LC3B-II were assessed using western blot analysis, and the autophagic activity was evaluated with the ratio of LC3B-II/LC3B-I. As shown in Fig. 5B ,E, the autophagy activity was upregulated after 12, 24, and 36 h TcdB treatment as the ratio of LC3B-II/LC3B-I was significantly increased. In contrast, cells showed a much lower ratio of LC3B-II/LC3B-I than the untreated cells (cell only) at each toxin treatment time point in the presence of 20 µM salubrinal, suggesting that the toxin-induced autophagy was abrogated by salubrinal, which may contribute to the protective effect of salubrinal against TcdB-induced cell death.
Discussion
Clostridium difficile TcdB is one of the major virulence factors of CDI and has been proved to induce apoptotic cell death through ER stress pathway in CT26 cell line according to our previous work [30] .
Salubrinal is a selective inhibitor of eIF2α dephosphorylation. In 2003, Paschen et al. [44] reported that 10 and 70 µM of salubrinal efficiently protect rat pheochromocytoma cell line PC-12 against death induced by tunicamycin-mediated ER stress [44] . Moreover, Gasparetto et al. [45] demonstrated that salubrinal reduced nephrotoxicity induced by cyclosporine mediated ER stress in rat. Recently Liu et al. [28] found that salubrinal protects cardomyocyte from tunicamycin and hypoxia-induced apoptosis via PERKeIF2α signaling pathway. We therefore hypothesized that salubrinal might protect CT26 cell line from TcdB-induced cell death, hoping that it will contribute to the development of new CDI therapies.
In this study, we successfully demonstrated for the first time that salubrinal is able to protect CT26 cells from TcdB-induced cell death. Remarkably, after exposed to TcdB only for 12, 24, and 36 h, CT26 cells showed obviously decreased viability and increased apoptosis. In contrast, the administration of 20 µM salubrinal effectively increased viability and inhibited apoptosis of the intoxicated cells, suggesting the protective effect of salubrinal.
To investigate the interaction between salubrinal and TcdB, the influence of salubrinal toward structure and function of TcdB was examined. TcdB showed normal cell-binding activity, glucosyltransferase activity, cysteine protease activity, and GTD release into host cytosol in the presence of 20 µM salubrinal, indicating that salubrinal does not influence the structure and function of TcdB. TcdB targets Rho-GTPase proteins in the host cytosol, inducing glucosylation at Thr 37 of Rho and Thr 35 of other GTPases, which leads to the inactivation of the GTPase proteins and blocking of Rho-dependent biological processes, including epithelial barrier functions, cell migration, actin cytoskeleton formation and so on. In order to reveal the mechanism of salubrinal's protection, the glucosylation of Rac1 in TcdB and salubrinal-treated cells was investigated. In 2002, Hippenstiel et al. [36] reported that Rho inactivation in TcdB-exposed endothelial cells would lead to the activation of caspase-9, and in 2007, Matarrese et al. [37] reported that TcdB-induced apoptosis is mediated by caspase-9. Thus, the cleavage of caspase-9 was also assessed using western blot analysis. Our results showed that salubrinal significantly reduced the level of Rac1 glucosylation at all time points and the level of caspase-9 cleavage at 12 and 24 h. After 36 h of treatment, the level of cleaved caspase-9 was increased obviously. It should noted that even the level of glucosylated Rac1 was attenuated in the presence of salubrinal, it was still much higher than that of untreated cells and cells treated with salubrinal only. Therefore, in the presence of salubrinal, more time is needed to induce cleavage of caspase-9 and caspase-9-dependent cell apoptosis. Second, PERK-eIF2α pathway is one of the three UPR branches, in which PERK phospharylates the α-subunit of eIF2, resulting in the attenuation of global translation initiation (Fig. 6) . CHOP is a key mediator of ER stressinduced apoptosis, and it is widely accepted that the expression of CHOP will increase when eIF2α is phosphorylated by PERK. Prolonged activation of CHOP can trigger apoptosis, and CHOPmediated apoptosis is related to the downregulation of Bcl-2. Because salubrinal is an inhibitor of eIF2α dephosphorylation, we detected the phosphorylation of eIF2α and expression levels of the downstream target CHOP and Bcl-2 in the TcdB and salubrinaltreated CT26 cells. When compared with that of cells treated with TcdB only, the enhancement of phosp-eIF2α/eIF2α was observed after 12 h of exposure to TcdB, and the ratio of phosp-eIF2α/eIF2α remarkably decreased for a longer time of TcdB treatment for 24 and 36 h. Our previous work reported that the level of phospeIF2α was significantly increased after 24 h intoxication [30] , which is different from the result here. But we assume that the general tendency of the phosp-eIF2α is consistent, i.e. increasing in short time of treatment and decreasing in long (over 24 h) time of treatment. An increase of Bcl-2 expression could be observed in the presence of 20 µM salubrinal. Moreover, consistent with our , and LC3B-II/LC3B-I (E) according to the immunoblots in (A) and (B), respectively. *means significant difference compared to untreated cells (cell only/control), *P < 0.05, **P < 0.01, ***P < 0.001. ns means no significant difference. # means significant difference between groups of TcdB only and TcdB + salubrinal, # P < 0.05; ## P < 0.01. CHOP, C/EBP-homologous protein.
previous study [30] , the protein expression level of CHOP decreased in the TcdB-intoxicated CT26 cells, which would not be altered by addition of 20 µM salubrinal. At this point, we concluded that salubrinal protects cells against TcdB-induced cell death via caspase-9-dependent apoptosis pathway and the eIF2α signaling pathway. But CHOP might not be involved in the TcdB-induced cell death [30] and the salubrinal might have no effect on the expression of CHOP. Autophagy is a degradation pathway that delivers cytoplasmic materials to lysosomes via double-membraned organelles called autophagosomes that enclose a portion of the cytoplasm [46] . It is believed to be involved in the degradation of intracellular bacteria [47, 48] , antigen presentation [49, 50] , tumor suppression [51] , cell survival, and death [52] . Research in autophagy has identified a number of autophagy-related genes, termed ATG genes [52] [53] [54] [55] . Most of the Atg proteins are highly conserved in mammals, among which LC3B is most commonly used for autophagy assay [56] [57] [58] . The LC3 protein can be detected as two bands in immunoblotting, one is the unconjugated form (LC3-I) and the other is phosphatidylethanolamine (PE)-conjugated form (LC3-II). The amount of LC3-II is closely correlated with the number of autophagosomes, therefore immunoblotting of endogenous LC3 can be used to measure autophagic activity [59] . Recent reports showed that salubrinal can abrogate autophagy caused by various factors and autophagy can regulate ER stress in ischemic preconditioning, so we also assessed the role of autophagy in TcdB-induced cell death and the effect of salubrinal toward autophagy in the TcdB-exposed cells. After exposure to TcdB for 12, 24, and 36 h, autophagy activity was upregulated in the intoxicated cells, as the ratio of LC3B-II/LC3B-I was dramatically increased, while administration of salubrinal could efficiently abrogate the autophagy induced by TcdB.
In summary, our data demonstrate that salubrinal prevents the glucosylation of Rac1 and subsequent cell death caused by C. difficile TcdB via caspase-9-dependent apoptosis pathway, eIF2α signaling pathway, and autophagy (Fig. 6) . It suggests that salubrinal can possibly be a potential candidate for therapies of CDI, which might represent a new approach in the development of new drugs for CDI. 
